Kaiser Permanente seamlessly connects health plan, physicians, specialists, hospitals, labs, and pharmacies to achieve better health outcomes for members.
Biosimilars play a critical role in lowering drug prices.
Kaiser Permanente successfully uses biosimilars to improve affordability for our members while saving our organization millions of dollars.
We’ve saved $200 million alone by switching to biosimilars for some cancer care.1
Our Advance Alert Monitor program, enabled by artificial intelligence, gives doctors an extra 12 hours for critical care diagnosis and treatment.
The program has led to more personalized, effective treatment plans and a reduction in death rates, the need for intensive care, the length of hospital stays, and the need for patient readmission.2
Artificial intelligence presents opportunities to improve patient outcomes and reduce health disparities in health care. It can support care teams and enable more personalized health care experiences. But health care leaders and policymakers alike must understand and address risks to ensure AI is used safely and equitably.3
1Mary Beth Lang, "Our Prescription for Safe, Effective, More Affordable Drugs," Kaiser Permanente, https://about.kaiserpermanente.org/news/our-prescription-for-safe-effective-more-affordable-drugs, July 11, 2023.
2Integrated Care Stories: Early warning system for hospitalized patients, Kaiser Permanente Institute for Health Policy, https://www.kpihp.org/integrated-care-stories/early-warning-system-for-hospitalized-patients/, 2023.
3Daniel Yang, MD, “Fostering responsible AI in health care,” Kaiser Permanente, https://about.kaiserpermanente.org/news/fostering-responsible-ai-in-health-care, March 19, 2024.